Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer.
Saved in:
| Title: | Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer. |
|---|---|
| Authors: | Hsu, Hung‐Chih1,2 (AUTHOR), Liu, Yu‐Chun2 (AUTHOR), Wang, Chuang‐Wei3,4 (AUTHOR), Chou, Wen-Chi1,2 (AUTHOR), Hsu, Yu-Jen2,5 (AUTHOR), Chiang, Jy-Ming2,5 (AUTHOR), Lin, Yung-Chang1,2 (AUTHOR), Yang, Tsai-Sheng1,2 (AUTHOR) a481124@cgmh.org.tw |
| Source: | Cancer Medicine. Jul2019, Vol. 8 Issue 7, p3437-3446. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.2235 |
